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BACKGROUND: Leptin and interleukin-1 (IL-1) upregulate vascular endothelial growth factor (VEGF), promote angiogenesis and are
related to worse prognosis of breast cancer. However, it is unknown whether leptin regulates IL-1, and whether these effects are
related to leptin-induction of VEGF/VEGFR2 in breast cancer.
METHODS: Several genetic and pharmacological approaches were used to determine the mechanisms involved in leptin regulation of
IL-1 system (IL-1a, IL-1b, IL-1Ra and IL-1R tI) and the impact of IL-1 signalling on leptin-induced VEGF/VEGFR2 expression in mouse
mammary cancer 4T1 cells (a model that resembles invasive and highly metastatic human breast cancer).
RESULTS: Leptin increased protein and mRNA levels of all components of the IL-1 system. IL-1 upregulation involved leptin activation
of JAK2/STAT3, MAPK/ERK 1/2, PI-3K/AKT1, PKC, p38 and JNK. Leptin-induced phosphorylation of mTOR/4E-BP1 increased IL-1b
and IL-1Ra expression, but downregulated IL-1a. Leptin upregulation of IL-1a promoter was linked to SP1 and NF-kB transcription
factors. In addition, leptin receptor (Ob-Rb) was upregulated by leptin. Interestingly, leptin upregulation of VEGF/VEGFR2 was
partially mediated by IL-1/IL-1R tI signalling.
CONCLUSIONS: We show for the first time that leptin induces several signalling pathways to upregulate the translational and
transcriptional expression of IL-1 system in breast cancer cells. Moreover, leptin upregulation of VEGF/VEGFR2 was impaired by
IL-1 signalling blockade. These data suggest that leptin pro-angiogenic signature in breast cancer is linked to, or regulated, in part by
IL-1 signalling.
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Obesity, a pandemic in the United States, is associated with more
than 100000 incidents of cancer in the United States every year,
particularly cancers of the breast, colon and endometrium. Obese
breast cancer patients have increased mortality compared with
non-obese (Whiteman et al, 2005). Obesity negatively impacts the
survival of breast cancer patients regardless of menopausal status,
as it has been positively associated with increased risk of
recurrence and increased proportion of breast cancer irresponsive
to oestrogens (Daling et al, 2001). The obese gene ligand (leptin), a
16-kDa cytokine, is mainly produced by adipose tissue. Higher
levels of leptin are found in female, postmenopausal women and
obese individuals. Leptin is a pro-angiogenic, pro-inflammatory
and mitogenic factor, the actions of which are reinforced through
crosstalk with cytokines/growth factors (Caldefie-Che ´zet et al,
2005; Gonzalez et al, 2006; Rene Gonzalez et al, 2009; Jarde et al,
2010).
Breast carcinoma cells express higher levels of leptin and its
receptor, Ob-R, than normal mammary cells (Miyoshi et al, 2006),
and a significant correlation between leptin/Ob-R levels with
metastasis and lower survival of breast cancer patients has been
found. Moreover, studies on leptin (ob/ob) and Ob-R (db/db)
mutant mice have provided compelling data supporting a role for
leptin in breast cancer development. These obese mice with
deficiency in leptin signalling show a significantly lower incidence
of mammary tumours than their lean littermates. MMTV/TGF-a
mice have a proclivity to develop mammary tumours, but when
crossed with leptin/Ob-R-deficient mice, there is a reduced
incidence of mammary tumours in their progeny (Cleary et al,
2003, 2004). Furthermore, our published data strongly suggest that
leptin is an important factor for breast cancer development. We
have shown that the inhibition of leptin signalling in vitro and
in vivo by our innovative leptin peptide receptor antagonists
(PEG-LPrA) significantly decreased the levels of vascular endo-
thelial growth factor (VEGF) and its receptor type 2 (VEGFR2)
before hypoxia is manifested (Gonzalez-Perez et al, 2010) in breast
cancer and stroma cells, while simultaneously reducing establish-
ment and growth of tumours in syngeneic (Gonzalez et al, 2006),
xenograft (Rene Gonzalez et al, 2009) and 7,12-dimethylbenz(a)an-
thracene-diet-induced obesity (unpublished) mouse models of
breast cancer.
One critical event for tumour growth and metastasis success is
the growth of a new network of blood vessels that can be promoted
by several cytokines derived from immune, endothelial, epithelial
and stromal cells. Leukaemia inhibitory factor, VEGF, interleukin-1
(IL-1) and leptin are known angiogenic factors expressed by
mammary cancer cells (Apte et al, 2006a,b). Aberrant inflamma-
tory response over normal immunity facilitates the development of
neoplasias. Increased levels of IL-1 are found in breast cancer
(Miller et al, 2000). IL-1 family, one of the major pro-inflammatory
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antagonist: IL-1 receptor antagonist (IL-1Ra) and two receptors:
IL-1R tI (type I receptor) and IL-1R tII (type II receptor) (Boraschi
et al, 1996). IL-1R tI is an 80-kDa protein, which has an intra-
cytoplasmic domain of about 215 amino acids. IL-1R tI, is the only
receptor responsible for transmitting signalling upon IL-1 binding.
In contrast, IL-1R tII, a 60-kDa protein with a short intra-
cytoplasmic domain (29 amino acids) serves as a decoy target that
reduces the levels of IL-1. IL-1Ra is an inhibitor protein that can
bind to IL-1R tI or IL-1R tII with similar affinity without triggering
cell signalling effects. Therefore, IL-1Ra represents a natural
inhibitor of IL-1 signalling (Apte et al, 2006a,b).
IL-1 is a known inducer of VEGF expression in different tissues
and has been described as a factor in cancer development (Carmi
et al, 2009; Valdivia-Silva et al, 2009). Macrophages are recruited
to tumours by chemokines, cytokines and growth factors,
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Figure 1 Leptin induces the expression of IL-1 system in 4T1 cells. (A) Representative results of leptin-induced increase in protein levels of IL-1 system as
determined by immunocytochemistry (magnification  40). Control cells in basal conditions: (Aa) no antibodies; (Ac) IL-1a antibodies; (Ae) IL-1b
antibodies; (Ag) IL-1R tI antibodies. Cells incubated with leptin: (Ab) no antibodies; (Ad): IL-1a antibodies; (Af) IL-1b antibodies and (Ah) IL-1R tI antibodies.
Protein levels of IL-1 ligands (B, IL-1a; C, IL-1b) and antagonist (D, IL-1Ra) as determined by ELISA (pgml
 1 per mg protein). (E), Protein levels of IL-1
ligands and receptor as determined by western blot (WB). (F) WB results were normalised to b-actin as a control and densitometric analysis of bands was
carried out with the imageJ software. mRNA levels of IL-1 ligands (G, IL-1a; I, IL-1b), antagonist (H, IL-1Ra) and receptor (J, IL-1R tI) as determined by real-
time RT–PCR. GAPDH was used as internal control. 4T1 cells were cultured for 24h and leptin dose-induced (0, 0.6, 1.2 and 6.2nM) effects were
determined as described (see Materials and Methods). (a) Po0.05 when comparing levels of protein or mRNA to control (basal). Data (mean±s.e.) are
representative of the results derived from a minimum of three independent experiments.
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sincluding VEGF, produced by tumour cells and other cell types in
the tumour microenvironment. In turn macrophages and tumour
cells secrete IL-1 that contributes to tumour progression by
facilitating angiogenesis, matrix remodelling, invasion and metas-
tasis (Chen et al, 2009). Strikingly, the inhibition of IL-1 signalling
by exogenous IL-1Ra negatively impacted tumour angiogenesis in
nude mice (Voronov et al, 2003).
Although, all the mechanism(s) by which leptin contributes to
tumour progression are unknown, our published data suggest that
specific leptin signalling increase cancer-cell proliferation and the
expression of VEGF/VEGFR2 in breast (Gonzalez et al, 2006; Rene
Gonzalez et al, 2009; Gonzalez-Perez et al, 2010; Guo et al, 2010)
and endometrial cancer (Carino et al, 2008), and in endometriotic
lesions (Styer et al, 2008). The associated expression of leptin
and IL-1 has been described in several pathological situations.
In endometrial cancer cells leptin induces the expression of IL-1
system (Carino et al, 2008). Leptin and IL-1 signalling can activate
NF-kB and increase the levels of VEGF and bcl-2 that could be
linked to breast cancer progression (Caldefie-Che ´zet et al, 2005).
Therefore, leptin and IL-1 may have synergistic functions in breast
cancer progression. Moreover, their relationships might be more
evident in obese (showing higher leptin levels) than in lean
individuals.
Despite that both leptin (Caldefie-Che ´zet et al, 2005; Gonzalez
et al, 2006; Rene Gonzalez et al, 2009; Gonzalez-Perez et al, 2010; Guo
et al, 2010) and IL-1 systems (Kumar et al, 2003; Voronov et al, 2003)
seem to have important roles in tumour angiogenesis and growth no
published data is available on the potential relationships between
leptin and IL-1 signalling in breast cancer. We hypothesise that the
leptin-induced progression of breast cancer could involve the
regulation of IL-1 system expression and activation of NF-kBa n d /
or SP1. Moreover, leptin-induced IL-1 could be related to leptin
upregulation of essential pro-angiogenic factors in breast cancer:
VEGF/VEGFR2. To test this hypothesis inhibitors of leptin-induced
kinases, RNA knockdown for transcription factors and luciferase
reporter for IL-1 gene promoter were used in mouse mammary 4T1
cells, a model that closely resembles human invasive/metastasic stage
IV breast cancer (Gonzalez et al, 2006; Gonzalez-Perez et al, 2010).
Present data suggest that leptin upregulates the IL-1 system at the
transcriptional and translational levels. Remarkably, leptin-induced
increase in VEGF and VEGFR2 levels were abrogated by the blockade
of IL-1 signalling. Therefore, leptin pro-angiogenic actions in breast
cancer may be linked to, or regulated in part by IL-1 signalling.
MATERIALS AND METHODS
Reagents and antibodies
Recombinant mouse leptin and mouse IL-1b, IL-1a, IL-1Ra and
VEGF ELISA Kits were from R&D Systems (Minneapolis, MN,
USA). Fetal bovine serum was obtained from Gemini Bioproducts
(West Sacramento, CA, USA), RPMI-1640 medium and penicillin–
streptomycin cocktails were from American Type Culture Collec-
tion (Manassas, VA, USA). Antibodies for IL-1R tI, Ob-R-NH2,
Ob-Rb-COOH, goat IgG2b, SP1 small interference (si) RNA and
control siRNA-A were obtained from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA). Antibodies for IL-1a, IL-1b, mTOR
and b-actin were from Abcam Inc. (Cambridge, MA, USA).
Antibodies for pERK 1/2/pMAPK (Thr202/Ty204), pmTOR
(S2448), p4E-BP1 (Ser65) and p70S6 Kinase-1 (Ser371) were from
Cell Signalling (Danvers, MA, USA). Anti-phospho AKT1/PKBa
(Ser473) was from Upstate (Lake Placid, NY, USA). Horseradish
peroxidase conjugates, iScript cDNA Synthesis, IQ SYBR Green
Supermix and protein determination kits were from Bio-Rad
Laboratories (Hercules, CA, USA). The ECL western blot stripping
buffer was from Thermo Scientific (Rockford, IL, USA). Dual-
luciferase assay system and control pGL-3 plasmid were obtained
from Promega (Madison, WI, USA). The NF-kB1 mouse short-
hairpin RNA was from Origene (Rockville, MD, USA). Nuclear
extract kit was from Active Motif (Carlsbad, CA, USA). The
RNeasy and DNase kits and Superfect transfect reagents were
obtained from Qiagen (Valencia, CA, USA). Wortmannin, AG490,
PD98059, Go ¨6976, SB203580, SP600125, Rapamycin, RIPA buffer,
Endofree plasmid maxiprep kit, protease inhibitor and phospha-
tase inhibitor cocktails and other chemicals were from Sigma-
Aldrich (St Louis, MO, USA).
Cell culture
The mouse mammary tumour cell line 4T1 (CRL-2539; American
Type Culture Collection) was cultured on uncoated flat-bottomed
plastic plates (cell densities of 1.0, 2.0 or 4.0 10
5 cells per well for
24-, 12- or 6-well plates as described elsewhere (Gonzalez-Perez
et al, 2010). Semi-confluent cells were starved for 24h in basal
medium (RPMI-1640 without fetal bovine serum) and treated with
different compounds. In all experiments triplicate wells, tubes and
reactions were run and repeated at least three times with different
cell preparations.
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Figure 2 Time–course response for leptin-mediated effects on the
expression of IL-1 system in 4T1 cells. Leptin effects on protein levels of
IL-1a (A), IL-1b (B), IL-1Ra (C) as determined by ELISA. Levels of
cytokines were normalised to basal condition (assigned as 1) and expressed
in arbitrary units. IL-1R tI (D) as determined by western blot (WB). (E)W B
results for IL-1R tI were normalised to b-actin as a control and
densitometric analysis of bands was carried out with the imageJ software.
4T1 cells were cultured in a medium containing 1.2nM leptin for 0–48h.
(a) Po0.05 when comparing levels of protein to control (basal). Data
(mean±s.e.) are representative of the results derived from a minimum of
three independent experiments.
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4T1 cells were starved as described above and incubated for 24h
with medium containing leptin (0, 0.6, 1.2 and 6.25nM, equivalent
to 0, 10, 20 and 100ngml
 1). Cell lysates and culture supernatants
were used to assess leptin dose–response effects on the levels of
IL-1 system component proteins and mRNAs as determine by
ELISA, western blot and real-time RT–PCR, respectively. For
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Figure 3 Leptin-induced signalling pathways involved in the regulation of IL-1 system in 4T1 cells. Effects of leptin and kinase inhibitors on levels of IL-1a
(A), IL-1b (B), IL-1Ra (C)a n dI L - 1 Rt I( D) as determined by ELISA and western blot, respectively. 4T1 cells were treated with leptin (0 or 1.2nM)f o r2 4hi nt h e
presence of inhibitors of JAK2/STAT3 (AG490, 30mM), MEK/MAPK/ERK1/2 (PD98059, 30mM), PI-3K/AKT1 (wortmannin, 20mM), PKC-Ca dependant (Go ¨6976,
30mM), p38 kinase (SB203580, 30mM), JNK (SP600125, 30mM) and mTOR (Rapamycin, 20mM) signalling pathways. WB results were normalised to b-actin as a
control and densitometric analysis of bands was carried out with the imageJ software. (a) Po0.05 and (b) Po0.01 when comparing levels of protein to control with
or without inhibitors (basal), respectively. Data (mean±s.e.) are representative of the results derived from a minimum of three independent experiments.
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1.2nM leptin for 0, 4, 8, 12, 24 and 48h. Protein concentrations in
cell lysates were determined by the Bradford method (Bio-Rad
Laboratories) and levels of IL-1R tI were assessed by western blot.
Specific kinases involved in leptin-mediated effects on
IL-1 system
4T1 cells were incubated with 1.2nM leptin and kinase inhibitors
(AG490 for JAK2/STAT3, 30mM; PD98059 for MEK/MAPK/ERK1/2,
30mM; wortmannin for PI-3K/AKT1, 20mM;G o ¨6976 for PKC-Ca
dependant, 30mM; SB203580 for p38 kinase, 30mM; SP600125 for
JNK, 30mM; and Rapamycin 20mM for mTOR) for 24h. Protein
levels of IL-1 system components in supernatants and cell lysates
were determined by ELISA and western blot, respectively.
Reporter gene transfection and luciferase assay
Semi-confluent 4T1 cells were transiently cotransfected with 50ng
of a Renilla reporter-luciferase control plasmid and 500ng of
pGL3-IL-1a plasmid (kindly provided by Dr Eugenie S Kleinerman
and Dr Ying Cao, University of Texas MD Anderson Cancer
Center). After 3h of cotransfection, cells were incubated with
1.2nM leptin for 24h and luciferase activity was determined.
Normalization was based on cotransfected Renilla luciferase
activities.
RNA extraction and real-time RT–PCR
RNA was extracted from 4T1 cells and first-strand cDNA was
synthesised using SuperScript II reverse transcriptase. The cDNA
was used as a template in real-time RT–PCR reactions, as
described elsewhere (Gonzalez-Perez et al, 2010). For generating
a standard curve, amplified cDNA was used in a five-fold dilution
series of 100–0.16ng cDNA per reaction. Relative gene expression
was calculated using the glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) expression value. Primers used in the experiment
were as following, mouse IL-1a forward: 50-TCGGGAGGAGAC
GACTCTAA-30 and reverse: 50-AGGTCGGTCTCACTACCTGTG-30;
mouse IL-1b forward: 50-TGCACTACAGGCTCCGAGAT-30 and
reverse: 50-CGTTGCTTGGTTCTCCTTGT-30; mouse IL-1Ra forward:
50-TGTGTTCTTGGGCATCCAC-30 and reverse 50-TTCTCAGAGCG
GATGAAGGT-3; mouse IL-1R tI forward: 50-GTCTTGGAGGGA
CAGTTTGG-30 and reverse: 50-CAGCTGAAGCCTCCCATATC-30;
mouse VEGFR2 forward: 50-GTGATTGCCATGTTCTTCTGGC-30
and reverse: 50-TTCATCTGGATCCATGACAA-30;m o u s eV E G F
forward: 50-TACCTCCACCATGCCAAGTGGT-30 and reverse: 50-A
GGACGGCTTGAAGATGTAC-30.T h eG A P D Hw a su s e da si n t e r n a l
control using the following primers: forward: 50-TGCACCACC
AATGCTTAG-30 and reverse: 50-GGATGCAGGGATGATGTTC-30.
Western blot analysis
Following cytokine and antibody treatment, cellular lysates were
prepared for western blot as described elsewhere (Gonzalez-Perez
et al, 2010). b-actin was used as control.
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Figure 4 Leptin induces the phosphorylation of mTOR, 4E-BP1 and
p70S6K1 in 4T1 cells. Representative western blot results for leptin-
induced activation of mTOR and its downstream targets (4E-BP1 and
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Figure 5 Leptin induces expression of IL-1a gene. (A) leptin transcrip-
tional activation of IL-1a reporter, (B) effects of siRNA for SP1 and NF-kB.
4T1 cells were transiently transfected with a IL-1a reporter construct and
treated with leptin (0 and 1.2nM) and siRNA-SP1 and shRNA–NF-kB for
24h. Luciferase activity was determined as described (see Materials and
Methods) and expressed as a percent of basal or leptin-treated cells.
(a) and (b) Po0.05 when comparing levels of luciferase activity to control
(basal) or leptin-treated cells, respectively. Data (mean±s.e.) are
representative of the results derived from a minimum of three independent
experiments.
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4T1 cells were incubated in basal medium for 24h (to synchro-
nise cells) and further incubated with 1.2nM leptin for additional
24h. Cells were re-dispersed, permeabilized and incubated with
antibodies for NH2 (all isoforms) and C-terminal (long-isoform)
Ob-R domains as described elsewhere (Gonzalez et al, 2003). Goat
anti-b-actin antibodies were used as positive control. Cells were
analysed by fluorescence-activated cell sorting (BD FACScan,
Becton Dickinson, Franklin Lakes, NJ, USA) and, data were
analyzed using BD FACSDiva (Becton Dickinson) and FlowJo
(TreeStar, Ashland, OR, USA) software.
Immunocytochemistry
To assess leptin effects on IL-1 system expression 4T1 cells (5 10
5
cells per chamber) were cultured in immunocytochemistry-treated
glass slides (BD Falcon, Belford, MA, USA) and incubated with
1.2nM leptin and antibodies for IL-1a, IL-1b and IL-1R tI
(Johnston et al, 2008). Negative controls have omitted the primary
antibody.
RNA knockdown
Semi-confluent 4T1 cells were cotransfected with SP1 siRNA
oligonucleotide, NF-kB1 shRNA and pGL3-IL-1a plasmids, and
treated with 1.2nM leptin for 24h. Luciferase activities were
determined as described above.
Blockade of IL-1R tI
4T1 cells were incubated with 1.2nM leptin and anti-mouse IL-1R
tI antibody or non-specific species-matched IgG2b (0.1mgml
 1).
mRNA levels and VEGF protein were determined by ELISA and
real-time RT–PCR, respectively. The VEGF and VEGFR2 proteins
in cell lysates were analyzed by western blot.
Data analysis
Student’s t-test was used for data analysis. Data are presented as
mean±s.e.m. Values for Po0.05 were considered statistically
significant. The model included the main effects of treatments and
replicates.
RESULTS
Leptin dose – response induction of IL-1 system
Leptin induced the expression of all IL-1 system components at
protein and mRNA levels (Figure 1). Leptin-mediated increase in
IL-1 protein levels was initially determined by immunohisto-
chemistry (Figure 1A). Leptin (1.2nM) increased protein levels
of IL-1a, IL-1b and IL-1Ra as determined by ELISA. Leptin
effects show bell-shaped dose–response patterns. Leptin upregula-
tion of IL-1 protein levels were found significant at 1.2nM
(Figure 1B–D). Moreover, leptin upregulation of IL-1 mRNA
showed significant changes at lower concentration, that is, 0.6nM
(Figure 1G–J). Western blot analysis showed that leptin at all
doses tested increased the levels of IL-1a, IL-1b and IL-1R tI
(Figure 1E and F).
Leptin time–course regulation of IL-1 system
Protein levels of all components of IL-1 system in 4T1 cells were
increased after 24h of incubation with leptin (Figure 2A–E).
Leptin signalling pathways involved in the regulation of
IL-1 system
Leptin increased the levels of IL-1a (Figure 3A), IL-1b (Figure 3B)
and IL-1Ra (Figure 3C). These effects were related to leptin-
induced canonical signalling pathways (JAK2/STAT3, MAPK and
PI-3K/AKT1). Meanwhile, leptin induction of IL-1b (Figure 3B)
and IL-1Ra levels (Figure 3C) was also related to mTOR activation.
However, mTOR seems to negatively regulate IL-1a (Figure 3A).
Furthermore, leptin regulation of IL-1b (Figure 3B) and IL-1Ra
(Figure 3C) to some extent involved JNK and PKC and p38 kinases.
In contrast, several leptin signalling pathways were involved in the
increase of IL-1R tI levels (Figure 3D).
We further assessed that leptin regulation of IL-1 system
involved the phosphorylation of mTOR downstream targets:
4E-BP1 and 70S6K1 (Figure 4). These leptin effects were abrogated
by rapamycin (Figure 4A). On the other hand, wortmannin
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Figure 6 Leptin upregulated OB-R in 4T1 cells. Representative
histograms from flow cytometric determination of leptin effects on the
expression of OB-R in 4T1 cells. (A) Positive control (b-actin antibody)
and negative control (isotype-matched unspecific IgG), (B) basal and
leptin-induced expression of OB-R all isoforms (anti-OB-R NH2-terminus
antibody), (C) basal and leptin-induced expression of OB-Rb (long isoform;
anti-OB-Rb COOH-terminus antibody). 4T1 cells were cultured in medium
containing 1.2nM leptin for 24h, incubated with specific antibodies and
analyzed by flow cytometry. Data derived from a minimum of three
independent experiments were analysed using BD FACSDiva and FlowJo
software.
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sabrogated AKT1 and 4E-BP1 phosphorylation, but no effects on
p70S6K1 were found (Figure 4B). In contrast, inhibition of pERK
1/2 did not affect p4E-BP1 or p70S6K1 levels (Figure 4C).
Leptin effects on the regulation of IL-1a promoter
Incubation of cells with leptin increased more than 50% the activity
of IL-1a promoter compared with control (Po0.05) (Figure 5A). The
RNA silencing of SP1 and NF-kB negatively affected leptin-mediated
induction of IL-1a reporter activity (Figure 5B).
Leptin upregulates its receptor in 4T1 cells
4T1 cells express Ob-R in basal conditions. Leptin induced a
similar increase of Ob-R total (22%; Figure 6B) and Ob-Rb (26%;
Figure 6C). These results suggest that leptin mainly increases the
expression of the full-functional Ob-Rb.
Impact of IL-1R tI blockade on leptin-induction of
VEGF/VEGFR2
Leptin induced almost two-fold and three-fold increase in the
levels of VEGF mRNA (Figure 7A) and protein (Figure 7C),
respectively. Similarly, leptin induced three-fold and two-fold
VEGFR2 mRNA (Figure 7B) and protein (Figure 7D), respectively.
The addition of IgG control antibodies did not alter leptin-mediated
effects on VEGF (Figure 7A and C) or VEGFR2 (Figure 7B and D).
The blockade of IL-1R tI function significantly impaired leptin’s
effects on VEGF and VEGFR2 (see Figure 7 A–D).
DISCUSSION
Leptin regulates inflammatory cytokines, including IL-1, in diverse
tissues and pathological conditions (Chala et al, 2006; Carino et al,
2008; Johnston et al, 2008). Nevertheless, published studies on the
relationships between leptin and IL-1 in breast cancer are scarce
(Miller et al, 2000). To address whether leptin could regulate IL-1
system in breast cancer, a mouse mammary cancer cell line 4T1
that closely resembles human invasive breast cancer was used.
Data from the present investigation show for the first time that
leptin upregulates the translational and transcriptional expression
of all IL-1 system components. Leptin activates several canonical
and non-canonical signalling pathways in 4T1 cells mainly leading
to increased levels of two transcription factors, SP1 and NF-kB that
were involved in IL-1 gene regulation. In addition, leptin-induced
activation of PI-3K signalling pathway was related to increased
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Figure 7 The blockade of IL-1R tI negatively impacts on leptin upregulation of VEGF/VEGFR2 expression in 4T1 cells. Effects of leptin and IL-1R
tI-blocking antibodies on levels of VEGF (A, mRNA and C, protein) and VEGFR2 (B, mRNA and D, protein) in 4T1 cells. Cells were incubated with leptin
(0, 1.2nM) and anti mouse IL-1R tI antibody (0.1mgml
 1) for 24h. Cells incubated with non-specific species-matched IgG2b served as negative controls. The
VEGF and VEGFR2 mRNA levels were quantified by real-time RT–PCR and normalised to the glyceraldehyde-3-phosphatase dehydrogenase expression.
The VEGF and VEGFR2 protein were determined by ELISA and western blot (WB), respectively. The VEGFR2 results from WB were analysed by
densitometric analysis (imageJ software) and normalised to b-actin as a control. (a) Po0.01 when comparing basal to leptinþcontrol Ab and (b) Po0.05
when comparing leptinþIL-1R tI to leptinþcontrol Ab. Data (mean±s.e.) are representative of the results derived from a minimum of three independent
experiments.
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slevels of pmTOR, p70S6K1 and p4E-BP. Leptin upregulation
of VEGF/VEGFR2 was partially dependant of IL-1 signalling
(Figure 8). Moreover, leptin upregulated its own receptor, Ob-R,
that could reinforce leptin actions on the expression of IL-1
system. These data strongly suggest that leptin pro-inflammatory
and pro-angiogenic effects are closely connected.
Immunosuppression provoked by excessive inflammatory
response could lead to increased tumourigenesis and tumour-cell
invasion (Voronov et al, 2003). Several studies suggest that the
IL-1 family of cytokines may be important in regulating
protumourigenic activities within the breast cancer microenviron-
ment (Miller et al, 2000; Pantschenko et al, 2003; Singer et al,
2003). IL-1b activates the NF-kB pathway and induces both cell
migration and proliferation (Wang et al, 2005; Lewis et al, 2006;
Streicher et al, 2007). Increased IL-1a expression correlated with
the expression of prometastatic (IL-6 and IL-8) and anti-apoptotic
genes (TRAF-1 and cIAP-2) (Bhat-Nakshatri et al, 1998; Newton
et al, 1999; Patel et al, 2000) and is associated with invasive and
metastatic cancer leading to poor prognosis (Miller et al, 2000).
Moreover, increased levels of IL-1, due to functional polymor-
phism of IL-1a gene, enhance hepatocellular carcino susceptibility
(Gao et al, 2009). Data from IL-1 KO mice strongly suggest that
IL-1 is a crucial factor in determining the balance between
immunity and inflammation in tumours (Voronov et al, 2010).
Tumour growth stimulation by IL-1 system appears to depend
on cancer cell–stromal cell interactions. Elevated production and
levels of IL-1 system components are found in invasive breast
cancer (Apte and Voronov, 2002). However, no studies have been
performed on the leptin regulation of IL-1 in breast cancer.
Furthermore, it is a lack of information on whether high levels of
leptin in obese patients parallel the levels of IL-1 in breast cancer.
Indeed, one of the factors secreted by tumour and adipose cells is
leptin, a small and pleiotropic cytokine, which could be involved
in the regulation of tumour-related inflammatory response.
Accumulating evidence suggest that leptin is an important player
in breast cancer growth and tumour angiogenesis (Vona-Davis and
Rose, 2009; Ray and Cleary, 2010). Elevated levels of leptin/Ob-R in
breast cancer are commonly linked to more invasive tumours and
worse prognosis (Cleveland et al, 2010). Both leptin and Ob-R are
over-expressed in cancer tissue relative to non-cancer epithelium
(Ishikawa et al, 2004). Therefore, our present results open the
possibilities to further explore these hypotheses.
Present results show that leptin induced the expression of the
Ob-Rb with full-signalling capabilities. Therefore, it is possible that
high levels of leptin found in the tumour microenvironment,
derived either from tumour or adipose cells, can upregulate the
expression of Ob-R by tumour cells leading to the increase of
tumour growth (Otvos et al, 2008) and expression of pro-
angiogenic and inflammatory factors (Guagnano et al, 2003).
In addition, leptin activates several genes involved in cell proli-
feration by upregulation of CDK2 and cyclin D1 levels (Dieudonne
et al, 2002; Okumura et al, 2002).
Leptin at concentrations similar to those found in the serum of
normal-weight individuals (i.e., 10–20ngml
 1)i n d u c e de x p r e s s i o n
of IL-1 system. Therefore, it is anticipated that higher concentra-
tions of leptin as those found in serum from obese individuals could
impact on the expression of IL-1 in breast cancer. Leptin-induced
expression of IL-1R tI involved several leptin-induced signalling
pathways. However, JAK2 and ERK1/2 were mainly involved in the
upregulation of IL-1 ligands and antagonist. These findings are in
agreement with leptin’s ability to upregulate Ob-Rb in 4T1 cells.
Ob-Rb is the only leptin receptor that can signal through pSTAT3
(Fru ¨hbeck, 2006). In addition, leptin-induced activation of PKC and
JNK signalling pathways increased IL-1Ra levels. Therefore, it could
be expected that biological processes leading to reduction of PKC
(i.e., by activated ras oncogene) (Weyman et al, 1988) or JNK (i.e.,
by NF-kB pathway) (Beevers et al, 2006; De Smaele et al, 2001) could
downregulate IL-1Ra and increase the actions of IL-1 agonists.
Present findings show that leptin-activated SP1 and NF-kB were
involved in the regulation of IL-1a promoter
Leptin-mediated activation of mTOR, a pathway deregulated in
many cancers (Beevers et al, 2006; Knight et al, 2006), was involved in
the regulation of IL-1 system. Indeed, leptin activation of pAKT1/
mTOR/p4E-BP1 increased the levels of IL-1b,I L - 1 R aa n dI L - 1 Rt Ii n
4T1 cells. Present data suggest that IL-1a promoter is under
regulatory effects of leptin through activated SP1 and NF-kB. It is
known that SP1 activation augments the angiogenic and metastatic
capacity of tumour cells through overexpression of multiple down-
stream genes, including VEGF (Shi et al, 2001). Currently, how leptin
activates SP1 in breast cancer cells is unknown.
Because both leptin and IL-1 are inflammatory and pro-
angiogeneic factors that upregulate VEGF, we hypothesised that
the association between IL-1 and leptin could be a critical event for
tumour angiogenesis. Consequently, the blockade of IL-1R tI
partially abrogated leptin-mediated increase of both VEGF and
VEGFR2 protein and mRNA. These data strongly suggest that
leptin pro-angiogenic signature in breast cancer could partially be
mediated by IL-1 signalling. These cytokines could actively
crosstalk in breast cancer eliciting pro-inflammatory and pro-
angiogenic effects that contribute to cancer growth.
CONCLUSIONS
Aberrant levels of inflammatory cytokines are a hallmark of breast
cancer. Present study further supports the idea that leptin has an
important role in breast cancer by increasing the expression of
pro-angiogenic and pro-inflammatory factors. Leptin upregulation
of IL-1 system could further enhance leptin’s actions in breast
cancer. Moreover, leptin and IL-1 could have synergistic functions
in breast cancer progression promoting VEGF/VEGFR2 expression
(Gonzalez et al, 2006; Rene Gonzalez et al, 2009; Gonzalez-Perez
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Figure 8 Signalling mechanisms for leptin regulation of IL-1 system in
4T1 cells. Leptin upregulated IL-1 system at transcriptional and translational
levels. Leptin canonical signalling pathways (JAK2/STAT3, MAPK and PI-3K/
AKT1) were mainly involved in the upregulation of IL-1 system. Leptin
activation of PI-3K/AKT1 was related to the phosphorylation of mTOR and
its downstream target, 4E-BP1, which is probably linked to upregulation of
IL-1b and IL-1Ra. In addition, mTOR negatively regulated IL-1a. Leptin
upregulation of IL-1a promoter involved the activation of SP1 and NF-kB.
Leptin-induced non-canonical signalling pathways (PKC, p38 and JNK)
differentially impacted on the expression of some components of IL-1
system. Leptin-induced upregulation of VEGF/VEGFR2 system was partially
mediated by IL-1/IL-1R tI signalling.
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set al, 2010) and tumour macrophage recruitment (Cao et al, 2001)
that could indirectly augment leptin-mediated angiogenic effects
and breast cancer growth. In addition, VEGF signalling transduc-
tion is also required to IL-1 induction (Mills et al, 2008). Therefore,
understanding of how these various factors cooperate to promote
tumour progression could lead to the development of more
effective combination therapies to fight breast cancer.
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